#United States #Brentwood #Meibum Scientific #Ryan S. Bleeks #BlephEx

Meibum Scientific Announces Ryan S. Bleeks as Interim CEO

In an exciting development for the ophthalmic medical device sector, Meibum Scientific has appointed Ryan S. Bleeks as their new Interim Chief Executive Officer. This transition comes at a pivotal moment for the company, as it looks to commercialize two flagship technologies: BlephEx and OptiVize.

Leadership Experience

Ryan S. Bleeks is an industry veteran with over 20 years of experience in the ophthalmic field. His previous role as CEO of Visiox Pharmaceuticals saw him successfully orchestrate a merger with Ocuvex Therapeutics, Inc. His significant background also includes managing the acquisition of the U.S. licensing rights for Omlonti® from Santen Pharmaceuticals, where he oversaw all phases of the transaction, from negotiation to successful integration. His extensive network and proven leadership in aligning commercial teams with brand strategies will be critical in executing Meibum's growth objectives.

James Rynerson, M.D., the founder of Meibum Scientific, expressed his enthusiasm about Bleeks's appointment, stating, "Ryan's appointment brings deep expertise in the ophthalmic market and meaningful partnerships across the eye-care ecosystem, strengthening the company's commitment to patient-focused innovation." With Bleeks at the helm, Meibum is poised to enhance its capabilities and lead the way in addressing significant challenges in ophthalmic health.

Focus on Innovative Technologies

BlephEx is notable for its in-office microblepharoexfoliation procedure that has been utilized by thousands of providers for over a decade. This procedure effectively removes accumulated lid-margin biofilm, promoting a healthier ocular surface environment, and it remains central to eyelid hygiene focused on biofilm management.

On the other hand, OptiVize represents a cutting-edge platform designed for intraglandular vaporization and thermal expression. This technology aims to eliminate deeply embedded biofilm inside the meibomian glands, utilizing electric current for biofilm vaporization coupled with heated vibratory expression. Together, BlephEx and OptiVize redefine what can be achieved in restoring gland functionality, representing a significant advancement in treating inflammatory dry eye.

Commitment to Patient Care

In his first remarks as Interim CEO, Bleeks shared his excitement about the prospect of tackling biofilm-induced inflammation and leading Meibum Scientific into its next growth phase. His commitment to patient care aligns with the company's mission to advance the science of dry eye disease, focusing on the persistent issues caused by biofilm-induced inflammation.

Meibum Scientific aims to translate groundbreaking scientific insights into practical, clinic-ready technologies, empowering eye care professionals to treat the underlying causes of inflammatory dry eye effectively. The appointment of Ryan S. Bleeks marks a major milestone in their journey toward innovation and leadership in the ophthalmic field.

Bleeks's extensive experience, combined with the promising technologies in Meibum's portfolio, sets the stage for substantial advancements in eye care. As the company pursues its mission, stakeholders and patients alike can expect innovative solutions to some of the most pressing challenges in ophthalmic health.

For more information about Meibum Scientific and their latest initiatives, visit MeibumScientific and connect with them on LinkedIn. Their commitment to patient-focused innovation and advanced healthcare technology promises to enhance the field of eye care significantly.